STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients

DSpace/Manakin Repository

STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients

Citable link to this page

 

 
Title: STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients
Author: Srivastava, Raghvendra M; Jie, Hyun-bae; Ferrone, Soldano; Ferris, Robert L

Note: Order does not necessarily reflect citation order of authors.

Citation: Srivastava, Raghvendra M, Hyun-bae Jie, Soldano Ferrone, and Robert L Ferris. 2013. “STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients.” Journal for Immunotherapy of Cancer 1 (Suppl 1): P175. doi:10.1186/2051-1426-1-S1-P175. http://dx.doi.org/10.1186/2051-1426-1-S1-P175.
Full Text & Related Files:
Abstract:
Published Version: doi:10.1186/2051-1426-1-S1-P175
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991086/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:12407007
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters